Barriers to new drug development in respiratory disease

This publication has 35 references indexed in Scilit:

• Respiratory health and disease in Europe: the new European Lung White Book
  European Respiratory Journal, 2013
• Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases
  Drug Design, Development and Therapy, 2013
• A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF-κB Inhibition
  The Journal of Pharmacology and Experimental Therapeutics, 2013
• A novel macrolide/fluoroketolide, solithromycin (CEM‐101), reverses corticosteroid insensitivity via phosphoinositide 3‐kinase pathway inhibition
  British Journal of Pharmacology, 2013
• Nortriptyline Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ
  The Journal of Pharmacology and Experimental Therapeutics, 2011
• Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease
  American Journal of Respiratory and Critical Care Medicine, 2010
• Assessing the translatability of drug projects: what needs to be scored to predict success?
  Nature Reviews Drug Discovery, 2009
• Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug
  Arthritis Research & Therapy, 2009
• Microfluidics for drug discovery and development: From target selection to product lifecycle management
  Drug Discovery Today, 2008
• Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems
  Proceedings of the National Academy of Sciences, 2007